A Phase I clinical trial is currently recruiting participants to evaluate a novel vaccine candidate against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), two significant causes of respiratory illness, particularly in vulnerable populations. The trial, coordinated by the University of the Sunshine Coast's (UniSC) Clinical Trials network, is taking place across three dedicated trial centers in Southeast Queensland, Australia.
The vaccine, developed by Vicebio, utilizes the University of Queensland's molecular clamp technology. This innovative approach aims to provide proactive protection against RSV and hMPV, both of which have seen a surge in infections in recent years. The trial seeks to determine the safety and immunogenicity of the vaccine compared to a recently licensed RSV vaccine.
The Need for New RSV and hMPV Preventatives
RSV and hMPV are common respiratory viruses that can cause severe illness, especially in young children, older adults, and immunocompromised individuals. These viruses lead to substantial hospitalizations and health complications, placing a significant burden on healthcare systems. According to Professor Keith Chappell, co-inventor of the molecular clamp, there is a "real need to explore new proactive protection and prevention options" against these viruses.
Trial Design and Participant Criteria
The Phase I trial aims to enroll 120 older adults aged 60 to 83. Participants must be in good health, although well-controlled chronic conditions are permitted. A key inclusion criterion is that volunteers must not have had a documented RSV and/or hMPV infection in the previous 12 months. Participants will be compensated for their time on the trial.
Potential Impact of the Vaccine
Dr. Emmanuel Hanon, Vicebio Chief Executive Officer, emphasized the potential of the vaccine to reduce the burden of disease associated with respiratory viruses. "RSV and hMPV cause substantial hospitalizations and health problems for our older adult community," Dr. Hanon stated. "The innovative Vicebio vaccine candidate could be a turning point in reducing the burden of disease associated with respiratory viruses, especially in vulnerable populations."
UniQuest, UQ's commercialization company, exclusively licensed the clamp technology to Vicebio for non-epidemic use. Proof-of-concept testing has paved the way for the technology to be used in a range of research programs.
